Skip to main content

Peer Review reports

From: A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial)

Original Submission
7 Dec 2017 Submitted Original manuscript
22 Dec 2017 Author responded Author comments - Athimalaipet Ramanan
Resubmission - Version 2
22 Dec 2017 Submitted Manuscript version 2
17 Jan 2018 Editorially accepted
27 Feb 2018 Article published 10.1186/s41927-018-0010-2

You can find further information about peer review here.

Back to article page